I don't see what's ironic about it. I would say it's "amazing"...

I don't see what's ironic about it. I would say it's "amazing" the extent to which we have turned the company around in the 12 months since we rebounded from the terrible announcement on 13 September last year, which would have killed most companies.
A quick recap: (1) we have successfully completed commercial-scale manufacture of Nasodine Nasal Spray on two continents (US and Australia); most pharma projects die at earlier stages of development, so we are way ahead and eliminated virtually all development risk; (2) we have made Nasodine available for sale in the US and Singapore, with all the logistics in place to support online sales; (3) we have recognised that the real game is pharmacy distribution and partnering, so we have put in place a new partnership in the Philippines (119m pop.) and expect to launch there in around 12 months with the product pushed through pharmacy distribution and doctors (at no cost exposure to FRE); (4) we have hired the former head of J&J APAC, Keith Shortall, to drive distribution and partnering throughout Asia, with massive potential upside; and (5) we just filed for approval of Nasodine in Europe as a nasal antiseptic, which could open up another 27 countries.
I think that after all we have achieved, as a shareholder, you either believe FRE has a great future, in which case you should buy up now while the SP is still low; or you don't - in which case you should sell. Either way, it allows you to stop complaining about the past decline in the FRE share price.

PM